The earnings call reflected a strong performance in financial metrics and strategic initiatives, such as revenue growth and clinical advancements. However, challenges in Germany and restructuring costs posed some concerns. Despite these difficulties, the company's proactive financial management and market expansion indicate a generally positive outlook.

Company Guidance

During the Hansa Biopharma second quarter earnings call for 2025, significant guidance was provided on various metrics. The company reported a 76% year-over-year increase in IDEFIRIX sales revenues for Q2 2025, amounting to SEK 47.9 million. For the first half of 2025, IDEFIRIX sales reached SEK 113.5 million, representing a 52% increase compared to the same period in 2024. Total revenues for the first half of 2025 saw a 27% increase from the previous year. The company successfully raised SEK 232 million in capital to support key data readouts in the latter half of 2025 and restructured existing debt with NovaQuest. This restructuring led to a modification of $14.8 million in outstanding debt into equity, with remaining fixed cash payments scheduled from 2027 to 2029. The company's cash runway is now extended into Q2 2026, and operational restructuring is expected to save approximately SEK 60 million annually. Despite a minor unfavorable increase in SG&A expenses, excluding restructuring charges, Hansa's SG&A expenses were 20% favorable compared to the previous year. The operating loss for Q2 2025 was SEK 154.8 million, showing a 17% improvement over Q2 2024.

Significant Revenue Growth

IDEFIRIX sales revenue for Q2 2025 was SEK 47.9 million, representing a 76% increase compared to Q2 2024. Total revenue in the first half of 2025 showed a 27% increase compared to the first half of 2024.

Successful Financial Restructuring

The company raised SEK 232 million and restructured existing debt with NovaQuest, ensuring a cash runway into Q2 2026.

Positive Clinical Trial Progress

Completed enrollment of the Phase III PAES study in kidney transplantation and the 15-HMedIdeS-09 Phase II study in Guillain-Barre syndrome delivered positive results.

Operational Cost Savings

Completed restructuring process with expected annual savings of approximately SEK 60 million.

Expansion in Market Access

Secured access in two additional markets, Australia and Switzerland, with IDEFIRIX now reimbursed in 20 countries.

Hansa Biopharma AB (SE:HNSA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SE:HNSA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	-1.41 / -	-1.53	―	―	―
Jul 17, 2025	2025 (Q2)	-1.66 / -2.53	-3.3	23.33% (+0.77)	―	―
Apr 24, 2025	2025 (Q1)	-2.67 / -0.55	-4.15	86.75% (+3.60)	―	―
Feb 06, 2025	2024 (Q4)	-1.98 / -4.08	-2.4	-70.00% (-1.68)	―	―
Oct 17, 2024	2024 (Q3)	-2.42 / -1.53	-4.78	67.99% (+3.25)	―	―
Jul 18, 2024	2024 (Q2)	-2.78 / -3.30	-4.79	31.11% (+1.49)	―	―
Apr 18, 2024	2024 (Q1)	-3.46 / -4.15	-3.92	-5.87% (-0.23)	―	―
Feb 02, 2024	2023 (Q4)	-3.72 / -2.40	-3.19	24.76% (+0.79)	―	―
Oct 26, 2023	2023 (Q3)	-3.98 / -4.78	-3.45	-38.55% (-1.33)	―	―
Jul 20, 2023	2023 (Q2)	-3.54 / -4.79	-1.91	-150.79% (-2.88)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SE:HNSA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 17, 2025	kr25.94	kr27.90	+7.56%
Apr 24, 2025	kr22.30	kr23.68	+6.19%
Feb 06, 2025	kr33.62	kr27.10	-19.39%
Oct 17, 2024	kr40.16	kr41.28	+2.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Hansa Biopharma AB (SE:HNSA) report earnings?

Hansa Biopharma AB (SE:HNSA) is schdueled to report earning on Oct 23, 2025, Before Open (Confirmed).

What is Hansa Biopharma AB (SE:HNSA) earnings time?

Hansa Biopharma AB (SE:HNSA) earnings time is at Oct 23, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Hansa Biopharma AB stock?

The P/E ratio of Hansa Biopharma AB is N/A.

What is SE:HNSA EPS forecast?

SE:HNSA EPS forecast for the fiscal quarter 2025 (Q3) is -1.41.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing